Biotechnology companies — particularly smaller and mid-sized ones — often reach a point where in-house expertise isn't enough to navigate commercial strategy, regulatory complexity, or market acc...
Patient centricity has become one of those phrases that gets nodded along to in every pharma strategy deck, yet rarely gets defined precisely enough to act on. Most organizations agree it matters...
